The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Rapee, R. M., Jones, M. P., Hudson, J. L., Malhi, G. S., Lyneham, H. J., & Schneider, S. C. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.10.004 · Cited by 14
A model of amygdala function following plastic changes at specific synapses during extinction
Bennett, M. R., Farnell, L., Gibson, W. G., & Lagopoulos, J. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100159 · Cited by 12
d-Cycloserine and estradiol enhance fear extinction in nulliparous but not primiparous female rats
Tang, S., & Graham, B. M. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.107088 · Cited by 16
Physiology of the Amygdala: Implications for PTSD
Rainnie, D. G., & Ressler, K. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-329-9_3 · Cited by 14
Self-citationSelf-Efficacy Beliefs Are Associated with Visual Height Intolerance: A Cross-Sectional Survey
Grill, E., Schäffler, F., Huppert, D., Müller, M., Kapfhammer, H., & Brandt, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116220 · Cited by 14
Panizzutti, R., Scoriels, L., & Avellar, M. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666140110121139 · Cited by 12
Pais, J. C., & Harvey, J. (2012) · CRC Press eBooks · doi:10.1201/b12767 · Cited by 12
Post, R. M., & Kegan, R. G. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.01.034 · Cited by 13
Mühlberger, A., Petrusek, S., Herrmann, M. J., & Pauli, P. (2005) · Zeitschrift für Klinische Psychologie und Psychotherapie · doi:10.1026/1616-3443.34.2.133 · Cited by 12
Combining Cognitive-Behavioral Therapy and Pharmacotherapy for the Treatment of Panic Disorder
Smits, J. A. J., O’Cleirigh, C. M., & Otto, M. W. (2006) · Journal of Cognitive Psychotherapy · doi:10.1891/jcop.20.1.75 · Cited by 12
Clinician's Guide to Medications for PTSD
(2009) · PsycEXTRA Dataset · doi:10.1037/e568712010-001 · Cited by 12
Pawlak, C. R., Chen, F., Wu, F.-Y., & Ho, Y. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.02.010 · Cited by 11
Assessment and Management of Posttraumatic Stress Disorder
Ellis, J., & Zaretsky, A. E. (2018) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000610 · Cited by 12
Bulteau, S., Laurin, A., Bach‐Ngohou, K., Péré, M., Vibet, M., Hardouin, J.-B., Sebille, V., Lagalice, L., Faurel-Paul, E., Acier, D., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020345 · Cited by 12
Posttraumatic Stress Disorder From Vietnam to Today
Benedek, D. M. (2011) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e318225f0e9 · Cited by 11
Heaton, L. J., McNeil, D. W., & Milgrom, P. (2010) · PubMed · Cited by 11
Siddik, M. A. B., & Fendt, M. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113961 · Cited by 12
The Future and Promise of Cognitive Behavioral Therapy: A Commentary
Zinbarg, R. E., Mashal, N. M., Black, D. A., & Flückiger, C. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.003 · Cited by 11
Dean, B., Möller, H., Svensson, T. H., Geyer, M. A., Rujescu, D., Scarr, E., & Millan, M. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001077 · Cited by 11
Pharmacological cognitive enhancers
Peltier, M. R., & Sofuoglu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815298-0.00023-x · Cited by 9
Stylianakis, A. A., Richardson, R., & Baker, K. (2019) · Behavioral Neuroscience · doi:10.1037/bne0000326 · Cited by 11
The Efficacy of Lidocaine in Disrupting Cocaine Cue-Induced Memory Reconsolidation
Becker, J. E., Price, J. L., Leonard, D., Surís, A., Kandil, E. S., Shaw, M. A., Kroener, S., Brown, E. S., & Adinoff, B. H. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108062 · Cited by 10
Simple and efficient synthetic routes to d-cycloserine
Kim, H., & Park, K. J. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.01.089 · Cited by 11
Novel Treatment Approaches for Refractory Anxiety Disorders
Pollack, M. H., Otto, M. W., Roy‐Byrne, P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.4.foc486 · Cited by 9
Self-citationSlattery, D. A., Neumann, I. D., Flor, P. J., & Zoicas, I. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.010 · Cited by 10
Lemke, J. R., Eoli, A., Krey, I., Popp, B., Strehlow, V., Wittekind, D. A., Vuorinen, A., Aldhalaan, H., Baer, S., Martin, A. D. S., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03279-4 · Cited by 10
Rothbaum, A. O., Tannenbaum, L., Zimand, E., & ROTHBAUM, B. O. (2023) · Virtual Reality · doi:10.1007/s10055-023-00760-9 · Cited by 9
Self-citationCross species review of the physiological role of d-serine in translationally relevant behaviors
Arizanovska, D., Emodogo, J., Lally, A. P., Palavicino‐Maggio, C. B., Liebl, D. J., & Folorunso, O. O. (2023) · Amino Acids · doi:10.1007/s00726-023-03338-6 · Cited by 9
Effects of d -cycloserine on individual differences in relapse of fear
King, G., Graham, B. M., & Richardson, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.02.005 · Cited by 9
Combining d-cycloserine and exposure-based CBT for the anxiety disorders.
Deveney, C. M., McHugh, R. K., Tolin, D. F., Pollack, M. H., & Otto, M. W. (2009) · Cited by 9
Rizzo, A., John, B., Williams, J., Newman, B., Koenig, S. T., Lange, B. S., & Buckwalter, J. G. (2012) · Cited by 9
LaBar, K. S., & LeDoux, J. E. (2006) · CRC Press eBooks · doi:10.1201/9781420004205.ch7 · Cited by 10
Perspective on the status of preclinical models for psychiatric disorders
Winsky, L., & Brady, L. S. (2005) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2005.11.007 · Cited by 9
Commentary on Riva, G., Virtual Reality in Psychotherapy: Review
GAMBERINI, L., & SPAGNOLLI, A. (2005) · CyberPsychology & Behavior · doi:10.1089/cpb.2005.8.231 · Cited by 9
Enhancing Fear Extinction: Pharmacological Approaches
Ponomareva, O. Y., Fenster, R. J., & Ressler, K. J. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_443 · Cited by 7
Self-citationRodgers, R. J., Howard, K., Stewart, S., Waring, P., & Wright, F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.08.005 · Cited by 8
Psychotherapy Augmentation through Preconscious Priming
Borgeat, F., O’Connor, K. P., Amado, D., & St-Pierre-Delorme, M.-È. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00015 · Cited by 8
Brunoni, A. R., & Palm, U. (2019) · Springer eBooks · doi:10.1007/978-3-319-95948-1_15 · Cited by 9
Arachnophobia and Fear of Other Insects: Efficacy and Lessons Learned from Treatment Process
Wiederhold, B., & Bouchard, S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8023-6_5 · Cited by 8
Gomes, F. V., Kakihata, A. M., Semedo, A. C. G., Hott, S. C., Uliana, D. L., Guimarães, F. S., & Resstel, L. B. M. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.009 · Cited by 8
Leslie, J. C., & Norwood, K. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.02.002 · Cited by 9
Tratamiento de los trastornos de ansiedad con terapia de exposición a realidad virtual
ROTHBAUM, B. O., García‐Palacios, A., & Rothbaum, A. O. (2011) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2011.05.003 · Cited by 8
Self-citationVirtual Reality in the Treatment of Psychiatric Disorders
ROTHBAUM, B. O. (2006) · CNS Spectrums · doi:10.1017/s1092852900024147 · Cited by 8
Self-citationPlasticity-augmented psychotherapy for refractory depressive and anxiety disorders
Choi, K., & Kim, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.003 · Cited by 8
Fear-Related Anxiety Disorders and Post-Traumatic Stress Disorder
Vahabzadeh, A. B. N., Gillespie, C. F., & Ressler, K. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00037-9 · Cited by 8
Self-citationDomschke, K., Kapfhammer, H., & Deckert, J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_69 · Cited by 9
Posttraumatic Stress Disorder: From Phenomenology to Clinical Practice
Benedek, D. M., & Ursano, R. J. (2009) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.7.2.foc160 · Cited by 8
Russo, A. S., Lee, J., & Parsons, R. G. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05195-2 · Cited by 7
Computer-guided cognitive–behavioural therapy for anxiety states
Peck, D. F. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.01.008 · Cited by 10
Virtual reality exposure therapy advances and potential for clinical and experimental use
ROTHBAUM, B. O., & Rothbaum, J. O. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01930-2 · Cited by 8
Self-citationCognitive-Behavioral Therapy Enhancement Strategies
Tolin, D. F., Lord, K. A., & Knowles, K. A. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.02.005 · Cited by 7
Neural systems involved in fear and anxiety based on the fear-potentiated startle test
Davis, M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372540-0/50013-3 · Cited by 6
Self-citationRandomized, Placebo-Controlled, Double-Blind Pilot Study of D-Cycloserine in Chronic Stroke
Butler, A. J., Kallos, J. A., Housley, S. N., LaPlaca, M. C., Traynelis, S. F., & Wolf, S. L. (2015) · Rehabilitation Research and Practice · doi:10.1155/2015/534239 · Cited by 7
Shen, Y.-F., Chou, Y.-H., Yang, Y.-L., & Lu, K. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2244-1 · Cited by 7
Animal models of exposure therapy
Todd, J. T., & Pietrowski, J. L. (2007) · Elsevier eBooks · doi:10.1016/b978-012587421-2/50003-x · Cited by 7
Diminich, E. D., Dickerson, F., Bello, I., Cather, C., Kingdon, D., Rouhakhtar, P. R., Hart, K. L., Li, C., Troxel, A. B., & GOFF, D. C. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.015 · Cited by 7
Stress modulation of fear and extinction in psychopathology and treatment
Drexler, S. M., Merz, C. J., Jentsch, V. L., & Wolf, O. T. (2020) · e-Neuroforum · doi:10.1515/nf-2020-0018 · Cited by 10
Cognitive Processes in Cognitive and Pharmacological Therapies
Tryon, W. W. (2009) · Cognitive Therapy and Research · doi:10.1007/s10608-009-9243-0 · Cited by 7
Chapter 50. Treatment of Anxiety Disorders
Choi, S., & Stein, M. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as50 · Cited by 7
Flor, H., & Hermann, C. (2006) · Verhaltenstherapie · doi:10.1159/000092951 · Cited by 7
A precision medicine approach to pharmacological adjuncts to extinction: A call to broaden research
King, G., Baker, K. D., Bisby, M. A., Chan, D., Cowan, C. S. M., Stylianakis, A. A., Zimmermann, K. S., & Richardson, R. (2019) · Psychopharmacology · doi:10.1007/s00213-018-4999-0 · Cited by 6
Dempsey‐Jones, H., Steudte‐Schmiedgen, S., Browning, M. D., Makin, T. R., Woud, M. L., Harmer, C. J., Margraf, J., & Reinecke, A. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986349 · Cited by 6
Maheux, J., Ethier, C., & Trépanier, E. (2022) · Service social · doi:10.7202/1089870ar · Cited by 14
Wu, I.-T., Tang, T., Ko, M.-C., Chiu, C.-Y., & Lu, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4042-7 · Cited by 6
Translating findings from basic fear research to clinical psychiatry in Puerto Rico.
Quirk, G. J., Martínez, K., & Nazario, L. L. (2007) · PubMed · Cited by 6
Fear of Heights (Acrophobia): Efficacy and Lessons Learned from Psychophysiological Data
Wiederhold, B., & Bouchard, S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8023-6_6 · Cited by 6
Molecular mechanisms of D-cycloserine in facilitating fear extinction: insights from RNAseq
Malan‐Müller, S., Fairbairn, L., Daniels, W. M. U., Dashti, M. J. S., Oakeley, E. J., Altorfer, M., Kidd, M., Seedat, S., Gamieldien, J., & Hemmings, S. M. J. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9727-4 · Cited by 5
A New Appraisal of Combined Treatments for PTSD in the Era of Psychotherapy Adjunctive Medications
Sheerin, C. M., Seim, R. W., & Spates, C. R. (2011) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-011-9195-z · Cited by 6
Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives
Normann, C., Nissen, C., & Frase, L. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0356-1 · Cited by 6
Strategies for managing symptoms of anxiety
Asmundson, G. J. G., Steven, T., Bovell, C. V., & Collimore, K. C. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.2.213 · Cited by 6
Byrne, S., Farrell, L. J., Storch, E. A., & Rapee, R. M. (2014) · Psychopathology Review · doi:10.5127/pr.033013 · Cited by 6
Wisłowska-Stanek, A., Lehner, M., Skórzewska, A., Maciejak, P., Szyndler, J., Turzyńska, D., Sobolewska, A., & Płaźnik, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.08.029 · Cited by 6
Godsil, B. P., Bontempi, B., Mailliet, F., Delagrange, P., Spedding, M., & Jay, T. M. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.169 · Cited by 7
Wenn Furcht und Angst entgleisen
Hamm, A. O., Weike, A. I., & Melzig, C. A. (2006) · Psychologische Rundschau · doi:10.1026/0033-3042.57.3.154 · Cited by 6
Otto, M. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.06.005 · Cited by 6
Fear Models in Animals and Humans
Hartley, C. A., & Phelps, E. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6599-7_1 · Cited by 7
Ollendick, T. H., Cowart, M. J. W., & Oar, E. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6599-7_6 · Cited by 5
Maladaptive Memory Mechanisms in Addiction and Relapse
Rich, M. T., & Torregrossa, M. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812202-0.00008-7 · Cited by 7
Extinction training for tinnitus
Struve, M., Diesch, E., & Flor, H. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)66044-0 · Cited by 6
The Use of Virtual Reality in the Treatment of Posttraumatic Stress Disorder (PTSD)
Simms, D. C., O’Donnell, S., & Molyneaux, H. (2009) · Lecture notes in computer science · doi:10.1007/978-3-642-02771-0_68 · Cited by 6
Neuroanatomical Structures Underlying the Extinction of Drug-Seeking Behavior
Cleva, R. M., & Gass, J. T. (2013) · The Open Addiction Journal · doi:10.2174/18749410010030200063 · Cited by 6
Neurobiologische Grundlagen von psychotherapeutischen Interventionen
Bohus, M., Mauchnik, J., & Schmahl, C. G. (2009) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.57.2.97 · Cited by 6
Tiermodelle für Angst und Angststörungen
Pawlak, C. R., & Weyers, P. (2006) · Psychologische Rundschau · doi:10.1026/0033-3042.57.3.139 · Cited by 6
Malan‐Müller, S., Fairbairn, L., Hart, S. A., Daniels, W. M. U., Dashti, M. J. S., Kidd, M., Seedat, S., Gamieldien, J., & Hemmings, S. M. J. (2017) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000176 · Cited by 6
Decoding threat neurocircuitry representations during traumatic memory recall in PTSD
Morris, K. A., Jaeb, M. A., Dunsmoor, J. E., Stowe, Z. N., & Cisler, J. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02028-5 · Cited by 6
Pharmacological enhancement of fear extinction
Davis, B., Rosenberg, B. M., Kearney, M. G., Treanor, M., Craske, M. G., & Barry, T. J. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.06.011 · Cited by 5
Finnegan, S., Harrison, O. K., Booth, S., Dennis, A., Ezra, M., Harmer, C. J., Herigstad, M., Guillaume, B., Nichols, T. E., Rahman, N. M., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00479-2022 · Cited by 5
Sepahvand, T., Nazari, N., Qin, T., Rajani, V., & Yuan, Q. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309986120 · Cited by 7
Klausing, A. D., Fukuwatari, T., DeAngeli, N. E., Bucci, D. J., & Schwarcz, R. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116350 · Cited by 5
Chapter 2.3 Extinction of fear: From animal studies to clinical interventions
Myers, K. M., & Davis, M. E. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00004-5 · Cited by 5
Self-citationEnhancing Exposure Therapy for PTSD Using d-Cycloserine
Burton, M. S., Youngner, C., McCarthy, A. J., Rothbaum, A. O., & ROTHBAUM, B. O. (2014) · Springer eBooks · doi:10.1007/978-1-4899-7522-5_18 · Cited by 5
Self-citationLong-term outcome of anxiety disorders: a review of double-blind studies
THUILE, J., EVEN, C., & Rouillon, F. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831a726d · Cited by 5
Healing anxiety disorders with glucocorticoids
Sandi, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103410108 · Cited by 5
Cold Pressor “Augmentation” Does Not Differentially Improve Treatment Response for Spider Phobia
Schmidt, N. B., Richey, J. A., Funk, A. P., & Mitchell, M. A. (2010) · Cognitive Therapy and Research · doi:10.1007/s10608-010-9310-6 · Cited by 5
Kappelmann, N., Suesse, M., Steudte‐Schmiedgen, S., Kaldewaij, R., Browning, M. D., Michael, T., Rinck, M., & Reinecke, A. (2019) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2019.101546 · Cited by 5
mGlu5: A double-edged sword for aversive learning related therapeutics
Tan, S., & Kim, J. (2021) · Neuroanatomy and Behaviour · doi:10.35430/nab.2021.e16 · Cited by 4
Settling the Score: Virtual Reality as a Tool to Enhance Trauma-Focused Therapy for PTSD
Rizzo, A., Hartholt, A., & Mozgai, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-56537-3_14 · Cited by 5
D-cycloserine nasal formulation development for anxiety disorders by using polymeric gels
Shin, Y., Kokate, R. A., Desai, V. S., Bhushan, A., & Kaushal, G. (2018) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2018.01017 · Cited by 5
Weems, C. F., & Neill, E. L. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00206-y · Cited by 5
Mechanisms of Fear Extinction: Toward Improved Treatment for Anxiety
Barad, M., & Cain, C. K. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511500008.008 · Cited by 5
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
